[Newsmp] The amount of cash equivalents of listed pharmaceutical companies decreased slightly in the first quarter.Among them, Dong-A ST rose to the KRW 200 billion mark, surpassing Yuhan Corporation, which retreated from KRW 200 billion.Newsmp compiled the cash & cash equivalent of the 64 listed ph

[Newsmp] Despite listed pharmaceutical companies posting double-digit sales growth in the first quarter, the combined retained earnings decreased slightly.Newsmp compiled the retained earnings of the listed pharmaceutical companies whose closing accounts are in NovemberㆍDecember and found that retai

[Newsmp] In the first quarter, major pharmaceutical companies’ sales related to cold medicine and antipyretics increased significantly.Since February, demand for cold medicines and antipyretics has risen remarkably due to the expansion of at-home treatment after the spread of the COVID-19 Omicron va

Newsmp] Exports of pharmaceutical companies listed on the Korea Exchange increased significantly in the first quarter.Newsmp compiled the quarterly reports of pharmaceutical companies that are closed accounts in November and December, and it was found that the combined exports of 55 companies jumped

[Newsmp] In the first quarter, 149 listed pharmaceutical and bio companies (manufacturing industry of medical materials and pharmaceuticals) whose closing accounts are in December achieved operating profits of KRW 1.2392 trillion.In particular, the operating profit of four bio companies, including H

[Newsmp] Starting players are slow in the high-end priced treatments market such as cell and gene treatments centered on CAR-T and SMA treatments.Kymriah (Novartis), which recently gained insurance coverage in Korea as the first CAR-T treatment, saw its quarterly sales decline for four consecutive q

[Newsmp] Major global big pharmaceutical companies expanded their sales significantly in the first quarter while the Omicron variant prevailed worldwide.In particular, the growth of companies with COVID-19 treatments or vaccines such as Pfizer, Moderna, AstraZeneca, and MSD was remarkable.The compan

[Newsmp] In the first quarter, it was found that sales of over-the-counter (OTC) drugs from top pharmaceutical companies increased significantly amid the continued shortage of OTC medicines such as cold medicines in the aftermath of the Omicron variant of COVID-19.According to Newsmp’s analysis of t

[Newsmp] In the first quarter, when the Omicron variant of COVID-19 was severe, all major pharmaceutical companies achieved good results.Newsmp compiled the disclosures of the five major pharmaceutical companies, and it was found that the average sales growth rate of them in the first quarter was 19

[Newsmp] In April, the bio-health exports sector reached a record monthly high.According to the Ministry of Trade, Industry and Energy (MOTIE), exports in the bio-health industry in April recorded $1.26 billion, up 14.2% from the same period last year, continuing double-digit growth for four consecu

[Newsmp] In the first quarter, Korea’s pharmaceutical trade deficit exceeded $900 million, with a deficit exceeding $300 million from the U.S. and Germany. On the contrary, Korea had a surplus of $300 million from Australia and $100 million from Taiwan.According to the Korea Customs Service, Korea’s

[Newsmp] Pfizer Pharmaceutical Korea’s retained earnings have soared by more than KRW 90 billion over the past year to KRW 300 billion.Newsmp tallied the income statements of multinational companies’ subsidiaries in Korea, whose closing accounts are between September and December, and found that of

[Newsmp] Multinational pharmaceutical companies’ subsidiaries in Korea are tightly cracking down on the amount of donations in the COVID-19 situation.Following 2020, the first year of COVID-19, the third and fourth pandemics continued throughout the last year, and they further reduced donations.News

[Newsmp] The cost of goods sold ratio (COGS) of multinational pharmaceutical companies’ subsidiaries in Korea was close to the 80% mark on average.Pfizer Pharmaceutical Korea, which has greatly is sales with the influence of the COVID-19 vaccine, has raised the average COGS ratio of multination phar

[Newsmp] Last year, Pfizer Pharmaceutical Korea recorded sales growth of more than 300% with the COVID-19 vaccine, and the average sales growth rate of multinational pharmaceutical companies was close to the 30% mark.Newsmp tallied the income statements of multinational companies’ subsidiaries in Ko

[Newsmp] In March this year, institutional investors who had largely liquidated their stake in Celltrion started courting again.Individual investors regained their loyalty to Shinpoong Pharmaceutical and Celltrion and bought Ildong Pharmaceutical.According to the Korean Exchange, institutional inves

[Newsmp] Six of the pharmaceutical companies ranked in the top 100 in annual sales among 1,328 KOSDAQ-listed components whose closing accounts are in December.According to the Korea Exchange’s KOSDAQ market fiscal year report, Seegene was the only pharmaceutical and bio company to achieve more than

[Newsmp] Exports in the biohealth sector including pharmaceuticals, which had gradually declined since their peak in December, have surged.According to the Ministry of Commerce Industry and Energy, Korea’s total exports in March reached $63.48 billion, an increase of 18.2% year-on-year and a record

[Newsmp] In 2020, the first year of COVID-19, the total R&D costs in the pharmaceutical manufacturing industry exceeded KRW 2 trillion.This is an increase of nearly KRW 400 billion from the previous year in 2019, and its proportion in the manufacturing sector has surpassed 3%.At the same time, R&D e

[Newsmp] Korean listed pharmaceutical companies’ entertainment costs, which had decreased due to COVID-19, has increased again.Newsmp compiled data from 44 listed pharmaceutical companies whose closing account is in November and December and found that the combined entertainment expenses amounted to